There have been many published studies over the years comparing the effects on spinal block using different intrathecal agents. The classic study design has been the randomised controlled trial and clinical endpoints have been principally height of sensory block and degree of motor block. Well worked out protocols have been developed 1 . However, the outcomes of these studies have been compromised by the wide range of block heights that result from an intrathecal injection and the confinement to a single, usually large, oneshot dose to guarantee satisfactory anaesthesia. Such a wide range of values affects the standard deviation of the main study outcomes such as sensory block height, and causes a lack of sensitivity when performing statistical comparisons. This limitation was apparent in a study of hypotension during spinal anaesthesia in the elderly in which I was involved in the 1990s 2 . In this study, groups of patients' sensory block commonly ranged from the lower thoracic region (T10) to the upper thorax (T4) (i.e. umbilicus to nipple line) following the same single-shot intrathecal dose of bupivacaine. Furthermore, having to use larger than needed doses of local anaesthetic in order to guarantee successful block and duration in all subjects prevents comparisons being made using the mean effective dose, or ED50, which is a much more specific endpoint for studying spinals and recommending dosage.
In this edition of Anaesthesia and Intensive Care, Kim and colleagues use a different study design based on dose response curves and probit analysis, to study spinal block in patients undergoing total knee replacement arthroplasty 3 . Probit analysis has been around since the 1930s and was first used in medicine to determine drug doses in toxicology 4, 5 . Probit analysis uses binary response variables such as success/failure to determine effective doses in 50 or 90% of subjects using regression modelling. Statistical packages that perform probit analysis are available commercially. Kim and colleagues used groups of patients who received between 6 to 11 mg (or 1.2 to 2.2 ml) of hyperbaric bupivacaine, and plotted success rates against bupivacaine dose.
To overcome the problem of failure to provide adequate spinal anaesthesia, they used a combined spinal and epidural (CSE) technique so that a failed block could be rescued by epidural anaesthesia. Their endpoints for success or failure were also very specific: bilateral T12 sensory block to pinprick within 15 minutes, requirement for supplementary epidural anaesthesia and report of leg tourniquet pain. By using two different variables in the study design, patient groupings and drug dosage, probit analysis allows one to more precisely define clinical endpoints. However, the use of the probit modelling using CSE to study spinal block in anaesthesia is not new. Both Ginosar and Carvahlo and colleagues have been using the method since 2004 in their obstetric anaesthesia research 6, 7 .
What is clinically interesting about Kim and colleagues' work is that they studied obese and non-obese subjects and using the probit and CSE approach they produced some very interesting findings that would not have been possible using a standard randomised controlled trial design. They showed that obesity had only a minor and non-significant effect on bupivacaine dose, but the duration of block was prolonged by about 20 minutes in the obese group. It has long been thought that obesity reduces the bupivacaine dose required to achieve a specific endpoint, the most likely mechanism being engorged epidural veins reducing cerebrospinal fluid (CSF) volume, so that an injected volume spreads further up the spinal canal 8, 9 . For this reason, lower volumes of intrathecal bupivacaine are used in obstetric anaesthesia. However, Kim and colleagues used hyperbaric solution, and the dynamics of heavy spinal solution spread in the CSF, compared to isobaric or plain solutions, is to flow to the most dependent point of the spinal canal, which is usually T6 when lying supine, as the spinal curves are followed, and thus the height of spinal block becomes independent of CSF volume. Kim and colleagues' data, admittedly from a cohort of 108 Korean patients, predicted an ED90 dose for successful block (i.e. reaching T12 level in 15 minutes) of around 2.0 ml bupivacaine 0.5% (heavy) for knee replacement surgery in both Morbidly obese subjects with a body mass index >40 kg/m 2 were not studied. However, their probit analysis of tourniquet pain, an index of duration of block, which is different from the height of block referred to previously by the ED90, showed that obese patients required a significantly smaller dose to achieve the same ED50 for the same block duration as in non-obese patients, indicating that hyperbaric bupivacaine takes longer to wear off in obese patients. Furthermore, these authors found that the increase in duration of block in the obese cohort was even longer when the higher and closer to clinically used doses of bupivacaine were used. The average overall reported increase in recovery time was about 20 minutes (i.e. 181 vs 163 minutes for time to first request for analgesia and 345 vs 323 minutes for time to first self-voiding of urine), which may not seem that relevant clinically. However, if one looks at data from their upper range of bupivacaine dose 9 to 11 mg, or 1.8 to 2.2 ml, which are closer to clinically used doses, the increase in recovery time, or duration of analgesia, becomes one hour longer for the obese patient cohort. Usually doses higher than 2.2 ml of bupivacaine 0.5% (heavy) are used in adult patients, suggesting even greater increases in duration of spinal block in obese patients.
So what does the paper by Kim and colleagues teach us about spinal block in the non-pregnant obese adult patient? These authors did not study morbidly obese patients who can be technically very difficult to manage, but patients who are only obese (without being morbidly obese), mean (range) body mass index 34 (29 to 39) kg/m 2 , who form a large part of our local patient populations. When performing spinal block in obese patients, a possible difference may exist between the use of plain and heavy local anaesthetic solutions. Studies in the late 1980s using plain or isobaric bupivacaine reported higher blocks in obese subjects 10, 11 . Subsequent studies attributed this finding to a reduced CSF volume as already discussed 8, 9 . Kim and colleagues' work suggests that this may not be the case when using heavy solutions, though they did not perform the same study with plain solution. Furthermore, their increased duration of spinal block in obese patients is an interesting and new finding of which all anaesthetists performing spinal block should be aware. It may lead to prolonged stays in recovery areas and affect discharge times. Finally, their data suggest that spinal doses of heavy bupivacaine should not be reduced when a patient is obese. 
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